why is compounded tirzepatide banned Explained: Key Facts to Know FDA BANS Compounded Tirzepatide! Now

The core issue is dosing precision and protocol adherence

AOD 9604 is a gentle, well-tolerated compound with modest fat-loss properties and a discontinued development program

The SELECT trial showed that semaglutide 2.4 mg (Wegovy) reduces cardiovascular risk in adults with established cardiovascular disease and either overweight or obesity, leading to an FDA-approved indication for reducing cardiovascular risk in this population

Why GI Side Effects Happen Tirzepatide's mechanism of action explains why gastrointestinal symptoms are common

Essentially, Ozempic interacts with one hormone receptor that controls digestion, while Tirzepatide interacts with two